Liquid biopsy results differed substantially between two providers in a study

AI-based blood test outperforms ultrasound in early liver cancer detection

Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, has released results from its latest clinical trial demonstrating the superior performance of their HelioLiver Dx test compared to ultrasound.

June 14, 2024

Vol.50 No.24

Drugs & Targets

FDA advisory committee recommends approval of Shield blood test for colorectal cancer screening

FDA’s Medical Devices Advisory Committee has strongly recommended FDA approval of Guardant Health’s Shield blood test for colorectal cancer screening in adults age 45 and older who are at average risk for the disease.

May 24, 2024

Vol.50 No.21

Clinical Roundup

Epigenomic platform may predict NSCLC immunotherapy response using liquid biopsies

Data published in The Journal for ImmunoTherapy of Cancer show ClearNote Health’s epigenomic platform may provide a novel tissue-free, liquid biopsy-based approach for prediction and monitoring of immunotherapy response for non-small cell lung cancer patients.

January 19, 2024

Vol.50 No.03

Regulatory News

Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approval
Meanwhile, NCI trial will assess clinical utility

Multi-cancer detection tests evoke conflicting reactions—the excitement at their promise is quickly dampened by concerns over the uncertainty of their clinical benefit, very low sensitivity for detecting stage 1 cancers, and the risks that come from subsequent workups.

Novel liquid biopsy of lymph fluid could guide precision treatment for head and neck cancer

Researchers from University of Pittsburgh and Washington University School of Medicine in St. Louis found that liquid from surgical drains, which is usually tossed in the trash, could inform more precise treatments for patients with head and neck cancer caused by human papillomavirus.

January 05, 2024

Vol.50 No.01

Guest Editorial

Liquid biopsy cancer screening: We’ll need more than one size to fit all

Liquid biopsy tests may someday upend screening as we know it. The promise of broad screening employing “multi-cancer detection” has spawned consortia and inspired enthusiastic opinion articles.

November 17, 2023

Vol.49 No.43

By Peter B. Bach

Liquid biopsy results differed substantially between two providers in a study

YOU MAY BE INTERESTED IN

AI-based blood test outperforms ultrasound in early liver cancer detection

FDA advisory committee recommends approval of Shield blood test for colorectal cancer screening

Epigenomic platform may predict NSCLC immunotherapy response using liquid biopsies

Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approval
Meanwhile, NCI trial will assess clinical utility

Novel liquid biopsy of lymph fluid could guide precision treatment for head and neck cancer

Liquid biopsy cancer screening: We’ll need more than one size to fit all

Renew today!

Subscriber content

Login

Liquid biopsy results differed substantially between two providers in a study

YOU MAY BE INTERESTED IN

AI-based blood test outperforms ultrasound in early liver cancer detection

FDA advisory committee recommends approval of Shield blood test for colorectal cancer screening

Epigenomic platform may predict NSCLC immunotherapy response using liquid biopsies

Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approvalMeanwhile, NCI trial will assess clinical utility

Novel liquid biopsy of lymph fluid could guide precision treatment for head and neck cancer

Liquid biopsy cancer screening: We’ll need more than one size to fit all

Login

Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approval
Meanwhile, NCI trial will assess clinical utility